This article is more than 5 years old. Information may no longer be current.
Tillotts, Numab partner to develop new anti-TNF therapies for IBD
Tillotts Pharma AG and Numab AG have announced their exclusive global licensing agreement for the development and commercialization of novel anti-tumor necrosis factor alpha therapies for the treatment of inflammatory bowel disease, according to a press release.
“Our agreement with Numab underlines our focus on innovation and commitment to developing cutting-edge therapies for the millions of patients suffering from gastrointestinal diseases,” Thomas A. Tóth von Kiskér, CEO at Tillotts, said in the press release. “Moreover, it supports our strategy to build a strong and balanced GI portfolio and R&D pipeline by combining our proven expertise in developing and marketing IBD treatments with Numab's breakthrough technology.”
The agreement terms dictate that new formulations of anti-tumor necrosis factor (anti-TNF) antibody fragments identified by Numab will be developed and commercialized by Tillotts, and Numab is eligible to a signing fee as well as down- and milestone payments and up to double-digit royalties upon successful development, the release said. Tillotts will also seek a co-development and marketing partner for the U.S. market after successful pre-clinical trials and submission of an investigational new drug application to the FDA.
“This collaboration is a further example of how Numab's stable antibody fragments can be combined with drug delivery technology to create novel routes of application for antibody therapies,” Oliver Middendorp, co-CEO and founder of Numab, said in the release. “We believe that Tillotts, with their commitment to innovation and strong expertise in GI diseases, is an ideal partner for this undertaking, which has the potential to result in best-in-class treatments for people with IBD worldwide.”
Disclosure: Tóth von Kiskér is an employee of Tillotts and Middendorp is an employee of Numab.